英国伦敦大学学院刘朝宗副教授：骨关节炎早期介入治疗:机遇与挑战

报告题目：骨关节炎早期介入治疗:机遇与挑战
报 告 人：刘朝宗（英国伦敦大学学院University College London，副教授）
报告时间：2017年12月19日（星期二）10:00-10:30
报告地点：大学城B12-410会议室
欢迎广大师生前往！

                                    生物医学材料与工程教育部重点实验室

                                          2017年12月15日

 报告人简介：
 Dr Chaozong Liu is an associate professor in Biomedical Engineering, the  programme leader of MSc in Musculoskeletal Science, and the group  leader of UCL Biomaterials & Osteochondral Tissue Engineering within  the Division of Surgery & Interventional Science University College  London. He has several years’ experience of biomaterials processing and  development of medical devices. Dr Liu’s current research is directed  toward the development of enhanced medical devices for treating  musculoskeletal disorders, tissue repair and regeneration. This is a  growing area of interest at UCL Surgical & Interventional Science.  His research in this area is supported by ARUK, Innovate UK,  Horizon2020, EPSRC MeDe Innovation Centre and RoseTree Trusts, and from  Fitzpatrick Referrals Ltd. He has developed a new osteochondral scaffold  technology that is likely to have a strong potential in regeneration of  bone and cartilage for early intervention of osteoarthritis.  Preclinical study has demonstrated that the new osteochondral scaffold  has the strength needed to bear the physical load of the joints and its  patented biomedical structure encourages consistent cartilage fill. A  glimpse of how this scaffold will perform has been given, with promising  results, by Professor Noel Fitzpatrick of the Channel 4 TV series  Supervet, where it was implanted in a pet dog shoulder to treat a large  osteochondral defect. His achievement on how bioengineering innovation  could treat and prevent OA in Arthritis Today (Winter 2017, No 174). The  recent awards from Innovate UK-MoST and EU HORIZON2020 have  significantly boosted his research in this field.
 报告摘要：
 UCL is one of the global top research intensive universities on a  research output dominated by its Biomedical and Engineering Faculties.  UCL’s contribution to the programme will be led by Institute of  Orthopaedics and Musculoskeletal Science (IOMS) which is an  internationally leading Centre of research and postgraduate training.  Its research straddling medical and bio-medical engineering  applications. It has reputation and track record for innovative  translation research, and has established expertise in technology  transferring such as Stanmore Implant Worldwide. UCL and staffs from the  Royal National Orthopaedic Hospital and other affiliated hospitals lead  units of major importance in clinical care and are at the cutting edge  of research and development in medical devices innovation,  cell-engineering and rapid fabrication of tissues, as well as healthcare  engineering. These have applications in musculoskeletal system  rehabilitation and vascular regeneration. Based at University College  London, we’re pioneering and developing the next generation of  healthcare innovations, aiming to optimise treatment and improve the  lives of patients across the globe. Our professional engineers and  skilled clinicians work side by side to enhance existing methods of  diagnosis, therapy and monitoring. UCL medical science provides a unique  environment for collaboration between scientists, engineers, and  clinicians in an Academic Health Sciences Centre model, in order to  speed up the development of improvements in patient care.